

1 Research article

2

3

4 **Changes in the quality of cancer care as assessed through performance indicators**
5 **during the first wave of the COVID-19 pandemic in 2020: a Scoping Review**

6

7

8 Changes in the quality of cancer care during the first wave of the COVID-19 pandemic in
9 2020: a Scoping Review

10

11

12 Ana Sofia Carvalho ^{1,2*}, MD

13 Óscar Brito Fernandes ¹, MSc, MEd

14 Mats de Lange ¹, MD

15 Hester Lingsma ², PhD

16 Niek Klazinga ¹, MD, PhD

17 Dionne Kringos ¹, MSc, PhD

18

19 ¹ Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam,
20 Amsterdam Public Health research institute, Amsterdam, the Netherlands

21 ²Department of Public Health, Erasmus MC - University Medical Centre Rotterdam, The Netherlands

22

23 * Corresponding author:

24 Ana Sofia Carvalho

25 Department of Public Health

26 Erasmus MC - University Medical Centre Rotterdam

27 The Netherlands

28 Email: a.s.carvalho@student.eur.nl

29

30

31 Abstract

32

33 **Objectives:** Summarize performance indicators used in the literature to evaluate the impact of the
34 COVID-19 pandemic on cancer care (January-June 2020), and to assess changes in the quality of care
35 as assessed via selected indicators.

36 **Methods:** Scoping review. Indicators and their reported trends were collated following the cancer care
37 pathway.

38 **Results:** Database searches retrieved 6277 articles, 838 articles met the inclusion criteria, and 135
39 articles were included after full-text screening, from which 917 indicators were retrieved. Indicators
40 assessing the diagnostic process showed a decreasing trend: from 33 indicators reporting on screening,
41 30 (91%) signalled a decrease during the pandemic (n=30 indicators, 91%). A reduction was also
42 observed in the number of diagnostic procedures (n=64, 58%) and in the diagnoses (n=130, 89%). The
43 proportion of diagnoses in the emergency setting and waiting times showed an increasing trend (n=8,
44 89% and n=14, 56%, respectively). Nine indicators (64%) showed stability in cancer stages
45 distribution. A decreasing trend in the proportion of earliest stage cancers was reported by 63% of
46 indicators (n=9), and 70% (n=43) of indicators showed an increasing trend in the proportion of
47 advanced-stage cancers. Indicators reflecting the treatment process signalled a reduction in the number
48 of procedures: 79% (n=82) of indicators concerning surgeries, 72% (n=41) of indicators assessing
49 trends in radiotherapy, and 93% (n=40) of indicators related to systemic therapies. Modifications in
50 cancer treatment were frequently reported: 64% (n=195) of indicators revealed changes in treatment.
51 Ten indicators (83%) signalled a decreasing number of hospital admissions.

52 **Conclusion:** Health systems struggled to ensure continuity of cancer care. As this pandemic keeps
53 evolving, the trends reported over the first 6 months of 2020 provide an argument to monitor these
54 changes closely. This information needs to be transparent, standardised, and timely, allowing to
55 monitor quality and outcomes of care during crises and inform policy responses.

56

57 **Keywords:**

58 1- Quality of Health Care [MeSH]

59 2- Quality Indicators, Health Care [MeSH]

60 3- Continuity of Patient Care [MeSH]

61 4- Cancer care

62 5- COVID-19

63

64

65 Introduction

66 The COVID-19 outbreak was declared a public health emergency of international concern by the
67 World Health Organization on the 30th of January, 2020 [1]. Since the beginning of the pandemic,
68 global health systems struggled to cope with the high numbers of patients infected with SARS-CoV-
69 2, while maintaining adequate care for non-COVID patients [2].

70 Cancer comprises a high burden to populations and health systems, being the second cause of death
71 globally [3], and in Organisation for Economic Co-operation and Development (OECD) countries [4].
72 The COVID-19 pandemic has widely affected cancer care delivery. Substantial declines in the number
73 of cancer diagnoses have been reported in the Netherlands [5,6], Spain [7], Belgium [8], and Denmark
74 [9]. While trying to minimize the risk of COVID-19 disease in cancer patients, changes in practice
75 were pursued by oncologists, according to each setting's capacity and recommendations released by
76 oncology societies [10–12] . Changes in the treatment prescribed were reported, by delaying, changing
77 treatment modality, duration, or mode of delivery [13].

78 Improving cancer care was already on the international health agenda prior to this pandemic, namely
79 in the 2030 Agenda for Sustainable Development adopted in 2015 at the United Nations Sustainable
80 Development Summit [14], in the Resolution “Cancer prevention and control in the context of an
81 integrated approach” approved in 2017 by the World Health Assembly [15]. At the same time,
82 systematic efforts to capture the outcomes of cancer care globally via cancer registries are in place
83 such as the CONCORD study [16,17]. The OECD reports on cancer care as part of its *Health at a*
84 *Glance* Series [4] and European Union (joint) actions have taken place [18]. During the COVID-19
85 pandemic, efforts continued to be pursued to improve prevention, diagnostics, treatment, and the
86 quality of life of cancer patients, among others with the launch of the “Europe's Beating Cancer Plan”
87 in November 2020 [19] and initiatives to monitor and report upon inequalities, such as the European
88 Cancer Inequalities Registry [20] and the launch of the European Commission's Knowledge Centre
89 on Cancer [21]. These efforts are necessary to tackle the cancer crisis and to address the backlog this
90 pandemic is creating [22–24].

91 One key area that needs strengthening is the development of performance indicators, its
92 standardization, and timely collection by health systems data infrastructures [25], to efficiently inform
93 on changes in the quality of care provided, allowing for comparisons within and between countries'
94 health systems. Although improving outcomes like 5-year survival is the ultimate aim, for guiding
95 health care delivery systems towards that goal, process and cancer-pathway based information is
96 essential.

97 The literature published on the consequences of the pandemic on cancer care is vast, therefore
98 assessing its impact requires a structured approach. This scoping review is part of a larger project,
99 which focuses on performance indicators on the care for non-communicable diseases (NCD). This
100 study aims to provide a systematic summary of cancer care performance indicators used in the
101 literature, regarding various cancers, across the care pathway, from early detection to outcomes, and
102 with an international coverage. Additionally, we set out to assess the main trends of the changes in the
103 quality of cancer care during the first wave of the COVID-19 pandemic, from January to June 2020,
104 by collecting and collating the performance indicators' trends across the cancer care pathway.

105

106

107 **Methods**

108 We conducted a scoping review, following Arksey and O'Malley methodological framework [26],
109 further developed by Levac *et al* [27]. Given the lack of standardized methods across countries for
110 data collection on health care system performance assessment and their translation to indicators
111 [25,28], a scoping review methodology allows to map the large sums and heterogeneity of literature
112 available [27,29,30] and to identify key concepts present in the literature [30], namely cancer care
113 performance indicators. It also enables the reporting of emerging evidence [29], to summarize, and
114 communicate findings [26], including trends revealed by indicators. The PRISMA extension for
115 scoping reviews [31] was used for reporting (S1 Table).

116

117 **Eligibility criteria of studies**

118 We considered the following inclusion criteria: 1) studies using empirical data on the use of health
119 services in OECD countries, 2) studies that described health outcomes and/or performance indicators
120 related with NCD during the COVID-19 pandemic, 3) original journal articles using quantitative or
121 qualitative methods (cohort studies, case-control, cross-sectional, case reports, systematic reviews,
122 surveys, and meta-analyses). Studies were excluded if they did not provide empirical data on health
123 services and NCD, namely: 1) editorials and commentaries, 2) prediction models, 3) clinical case
124 reports; 4) diseases management or health services organization guidelines, 5) studies about the impact
125 on healthcare workers, patients diagnosed with COVID-19, children, or pregnant women; 6) studies
126 primarily performed in non-OECD countries. No limitations were set regarding language or year of
127 publication.

128

129 **Information sources**

130 MEDLINE and Embase databases were selected to search for this study, given the large number of
131 articles and their comprehensive coverage of the literature on health services delivery. Pilot searches

132 were conducted to identify a list of suitable search terms. An experienced medical information
133 specialist was consulted to improve the search strategy, which was refined with discussion among co-
134 authors. The comprehensive search included search terms grouped by key concepts (COVID-19,
135 pandemic, non-communicable disease, chronic disease, performance indicator, healthcare quality,
136 healthcare utilization, healthcare delivery and other closely related terms). The search was adapted to
137 both databases and conducted by the information specialist on 17-03-2021. The full search strategy for
138 Embase can be found in S2 Doc. Duplicates were removed using EndNote software. Additional articles
139 of relevance were added by hand-searching the reference lists of the included studies.

140

141 **Selection of sources of evidence**

142 Titles and abstracts screening was performed independently by two researchers (ASC, OBF) using
143 Rayyan [32]. Studies considered relevant were exported to a spreadsheet to support full-text screening.
144 For this study, only articles related to cancer care were analysed. Full-text screening was performed
145 independently by two researchers (ASC, MdL). The reason for the exclusion of articles was recorded
146 at this point, and both researchers agreed on the excluded studies. In case of doubt, the other co-authors
147 were consulted.

148

149 **Data extraction**

150 Data extracted was collated in a spreadsheet (S3 Table) piloted on 15 studies. Prior to extracting data
151 from all studies, two researchers (ASC, MdL) compared data collected from 10 selected articles with
152 the objective of enhancing data extraction consistency among researchers. Then, data was charted
153 independently by ASC and MdL. Extracted data included information on generic and methodological
154 aspects of the article (e.g., authors, title, setting) and information about the indicators collected (e.g.,
155 indicator title, and data inclusion/exclusion considerations). For every indicator, we identified the trend
156 reported in the articles (increase/decrease/stable), if any.

157

158 **Synthesis of results**

159 We grouped and categorised the indicators following clinical reasoning. These categories were
160 organized according to the different phases of the cancer care pathway: early detection, diagnosis,
161 treatment, and outcomes. Quantitative indicators' trends were collated, and the percentage of indicators
162 reporting each trend (increase/decrease/stable) was computed for each category. This evidence is
163 presented in the text of this study and in a diagram informing about each phase of the cancer care
164 pathway. Qualitative information extracted from surveys is presented in the text, and it was not
165 considered to compute trends. In the category “changes in treatment” quantitative indicators and
166 qualitative information were grouped and categorized according to clinical reasoning to present an
167 overview of the modifications in cancer treatment reported.

168

169

170 **Results**

171 Database searches retrieved 6277 articles. Of these articles, 838 met the inclusion criteria, from which
172 197 articles on cancer care were identified. Eight records were identified via hand-searching. After
173 full-text screening, 135 articles were included in this study (Fig. 1).

174

175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208




Fig. 1 - PRISMA flow diagram of the literature search (17-03-2021)

209 General characteristics of the included articles

210 In total, 135 studies were included, reporting on 94 countries (S4 Table). Of these studies, 26 (19%)
211 provided information on multiple countries, from which 14 (10%) specified all the countries included.
212 Of those, 8 (6%) included non-OECD countries. Most of the studies including more than one country
213 were surveys (n=23, 89%). The most frequent countries reported on were Italy (n=36, 29%), US (n=32,
214 26%) and UK (n=27, 22%) (Fig. 2). Most articles used a retrospective cohort design (n=82, 61%),
215 followed by surveys (n=44, 33%). Surveys were often directed to health professionals (n=37/44, 84%)
216 and to patients (n=6/44, 14%) to a lesser extent. Other study designs that were applied included
217 prospective cohorts (n=5), observational retrospective cohorts (n=3), and a combination of prospective
218 and retrospective cohort (n=1). Studies reported indicators' trends during the first phase of the COVID-
219 19 pandemic (from January to June 2020) and, in some cases, after the (in many countries
220 implemented) lockdown period (from May to October 2020). The magnitude of each indicator in 2020
221 was compared with its magnitude in the same period of 2019 (n=51, 38%), to a period immediately
222 before (n=33, 24%) or to the average of the same period in previous years (ranging from 2017 to 2019)
223 (n=26, 19%).




Fig. 2 – OECD countries reported on, color-graded according to the number of papers (n=122 articles; 90% of included articles).

240 **Cancer Care Indicators**

241 A total of 917 quantitative indicators from 91 articles were retrieved and grouped into categories (Table
242 1).

243 **Table 1 – Cancer care indicators’ categories retrieved in the literature review**

Early detection
Number of screening procedures
Early diagnosis and predisposition exams
Screening detection rates
Diagnosis and staging
Number of diagnostic, surveillance, and staging exams/procedures
Number of cancer diagnoses
Delay in access to diagnostic procedures
Cancer detection rate
Proportion of urgent/emergent referrals and procedures
Changes in cancer staging
Clinical severity at diagnosis
Treatment
Number of referrals / first encounters
Outpatient volume
Number of treatments
<ul style="list-style-type: none"> Cancer-related surgeries & loco-regional therapies Radiotherapy treatments Systemic anticancer therapy
Delay in treatment
Changes in treatment
Number of visits and admissions in hospital
Virtual multidisciplinary meetings
Telemedicine utilization
Outcomes
Surgical and procedures outcome measures
Mortality

244 *Note:* A total of 338 indicators were not included in the analysis since they were too specific to be grouped into the defined
245 categories.

246

247 The first stage of the care pathway looks at **early detection**. Regarding the “number of screening and
248 other early diagnosis procedures”, a total of 33 indicators from 13 articles [33–45] have been reported.
249 Most indicators on the number of screening procedures signaled a decreasing trend (n=30, 91%),
250 namely in US, UK, and Italy. One international survey answered by physicians [46] (including Italy,
251 Iran, Spain, UK, US, China, Denmark, Sweden, and Switzerland) reported the suspension of breast
252 screening programs in all countries, except 2. Only one American paper [38] addressed cervical cancer
253 screening, showing a decrease in number of screenings during stay-at-home order, compared with
254 2019. Three articles [35,39,42] addressed colorectal cancer screening, from US, UK and Spain and
255 have also revealed a reduction when compared with previous year.

256 Seven papers [33,34,36–38,40,42] reported on “early diagnosis and predisposition exams”, namely:
257 screening visit for prostate cancer (US), gBRCA testing (Italy), HPV tests rate, low-dose computed
258 tomography and prostate-specific antigen measurement (all from the US). All these indicators have
259 shown a decreasing trend in the number of diagnostic procedures.

260 “Screening detection rates” were reported by 14 indicators from 5 articles [22,36,37,47,48], from the
261 US and Italy. Most of the indicators (n=9, 75%) showed an increase in screening detection rates. These
262 included an increase in high-risk adenomas and colorectal cancer detection rates during the lockdown
263 period, along with a decrease in low-risk adenoma detection rates in one Italian study [47].

264

265 The next stage of the care pathway focuses on **diagnosis and staging**. The “number of diagnostic,
266 surveillance and staging procedures” was reported in 17 articles [41,43–45,48–60] (from the UK, Italy,
267 US, France, Australia, the Netherlands, Turkey, Ireland, and Slovenia), comprising a total of 90
268 indicators. Most of those indicators (n=58, 64%) showed a decreasing trend in the number of
269 procedures, namely cystoscopy, diagnostic mammograms, breast cancer wire-guided biopsy,
270 gastroscopy, colonoscopy, computed tomography (CT), magnetic resonance imaging (MRI), and
271 endoscopic retrograde cholangiopancreatography.

272 A total of 147 indicators from 35 articles [9,35,39,47,48,52,54,55,59–83] reported on the “number of
273 cancer diagnosis”. Most of these indicators (n=130, 89%) signalled a decrease in the number of cancer
274 diagnoses. Data came from registries in the Netherlands, Denmark, Germany, and Italy, cytology
275 laboratories, tumor boards numbers, and administrative sources. One international survey to
276 laboratories from 23 countries [66] showed an absolute reduction in the number of cytological samples
277 regarding all anatomic sites.

278 Five studies [37,55,67,75,82] (from the US, UK, France, and Italy) addressed the number of cancer
279 diagnoses after the lockdown period (10 indicators). Three of these indicators (30%) showed a higher
280 number of diagnoses, when compared with the period of lockdown.

281 Five surveys [84–88] reported “delays concerning different aspects of cancer diagnostics”. One
282 international survey [85] focusing on colorectal cancer care, with professionals from 84 countries,
283 reported delays in radiologic exams and endoscopic procedures. Other surveys mentioned limited
284 access to hospital facilities (Italy) [89], delays in tissue diagnosis (UK) [88], delays in diagnostics of
285 patients with neuroendocrine tumors (Germany, Austria, Switzerland) [87], and genetic testing or
286 counseling (US) [86]. The other two articles [43,90] addressed the delays in access to diagnostics,
287 comprising a total of 9 quantitative indicators, from which 8 (89%) signalled an increase in the waiting
288 time to diagnostic procedures.

289 The “cancer detection rate in referrals and diagnostic exams” was assessed in 5 articles, from UK
290 [59,91], Italy [48], Ireland [43], and one international survey of 23 laboratories worldwide [66]. The
291 13 indicators collected signalled an increasing trend in cancer detection rate in 9 indicators (69%). The
292 survey reported an increase of 5.5% in the malignancy rate in nongynecological samples, when
293 compared with the corresponding period in 2019.

294 Twenty-five indicators from 5 studies [39,57,59,92,93] (from Spain, UK, Australia, and Croatia)
295 reported on the proportion of “urgent/emergent referrals and procedures”. Most of these (n=14, 56%)
296 showed an increase in the proportion of urgent procedures (endoscopy and colonoscopies), diagnosis
297 in emergency setting or operations that followed an emergency admission.

298 The indicators that reported on “changes in cancer staging” were grouped in 3 different categories:
299 general staging indicators (14 indicators from 8 articles [75,77,81,94–98]), proportion of earliest-stage
300 cancers (35 indicators from 9 articles [41,71,81,99–104]), and proportion of advanced-stage cancers
301 (61 indicators from 17 articles [39,57,63,66,77,79,87,92,93,95–102]).

302 Most of the general staging indicators (n=9, 64%) showed stability in cancer stages distribution at
303 diagnosis, when comparing the pre- and post-lockdown periods (data from Italy, US, UK, France, US,
304 and Portugal). These indicators included stages of gynecological cancer, breast cancer, lung cancer,
305 and hepatocellular carcinoma. With respect to the proportion of earliest stage cancers, most of the
306 indicators (n=9, 63%) showed a lower proportion of these cancers when compared with pre-pandemic
307 period, 9 (26%) signalled a stable trend, and 4 (11%) showed an increasing trend. From the indicators
308 reporting on the proportion of advanced-stage cancers, 43 (70%) showed an increasing trend in this
309 proportion after the beginning of the pandemic, 14 (23%) signalled a stable proportion, and 4 (7%)
310 reported a decreasing trend.

311 Fourteen indicators from 7 articles [41,47,57,69,97,100,105] evaluated the “clinical severity at
312 diagnosis”, which included symptoms, scores, and biomarkers. The majority (n=8 indicators, 57%)
313 showed patients presenting in a more severe clinical condition than before the pandemic, namely in
314 US (endometrial cancer), Portugal (hepatocellular carcinoma), Italy, and Turkey (colorectal cancer).

315 The following stage of the care pathway reported on is **cancer treatment**. A total of 41 indicators
316 (from 9 articles [35,60,65,72,91,96,103,106,107]) reported on the “number of cancer patients’
317 referrals”. Most of the indicators (37, 90%) signalled a decrease in the number of first encounters for
318 oncological examination, namely in Slovenia, UK, US, France, Spain, and the Netherlands. Four
319 surveys (from UK [88], US, Italy [108] and one international study [109] reported a decrease in the
320 number of new referrals.

321 A total of 47 indicators were identified from 14 articles
322 [35,42,44,52,55,60,65,90,91,93,96,106,110,111] regarding the outpatient care of patients diagnosed
323 with cancer. Of these indicators, 46 (93%) showed a decrease in the number of outpatient visits (in

324 Korea, US, France, UK, Spain, Slovenia, and Italy). Thirteen surveys [13,46,70,86,87,89,108,112–
325 117] disclosed information concerning outpatient care. Ten were answered by oncologists and 3 were
326 answered by patients. The latter studies reported consequences on treatment or follow-up
327 (Netherlands) [114], namely treatment adjustment, postponement, delay, or discontinuation; delay in
328 routine or follow-up clinic appointment (US) [86] and postponements of physician appointments
329 (Germany). A substantial percentage of physicians reported cancellation or deferral of follow-up visits.

330 Regarding the “volume of cancer treatment”, indicators regarding the 3 main therapeutic components
331 were reported: surgeries and loco-regional therapies, radiotherapy, and systemic therapy.

332 Concerning surgeries and loco-regional therapies, 106 indicators were identified from 30 articles
333 [42,48–51,55,62,65,65,75,81,90,92–94,97–99,101–103,111,118–125]. Of those, 82 indicators (79%)
334 showed a reduction in the number of treatment procedures, namely in Italy, France, Germany, Ireland,
335 Netherlands, Spain, Turkey, UK, US, Australia, and in 1 international study. Nineteen articles were
336 surveys directed to physicians [46,58,70,78,84,85,88,90,108,115,126–134], out of which 8 were
337 international. All have shown significant reductions in surgical activity regarding different cancers.

338 Regarding radiotherapy treatments, 57 indicators from 8 articles [55,90,92,121,135–138] were
339 identified. Most of these indicators signalled a reduction of the number of treatments (n=41, 72%),
340 namely in UK, US, and Canada. Five international surveys to physicians [112,114,126,132,137] also
341 reported that this type of cancer therapy was affected.

342 With respect to systemic anticancer therapy, 43 indicators were identified from 9 articles
343 [42,53,55,72,96,106,111,139,140], concerning Italy, France, UK, Spain, and the US. The majority
344 (n=40, 93%) showed a decrease in requests for initial treatment and in the number of chemotherapy
345 administrations. Six surveys [58,109,112,115,134,141] reported on this treatment modality. One study
346 including 54 countries [46] showed that 88.2% of centers reported a reduction in their usual level of
347 care, while 9.83% of those reported lack of access to medications. A European study with 29 countries
348 [109] reported that 6% of centers revealed shortages of drugs.

349 A total of 28 indicators (from 3 articles) [55,139,140] reported on systemic anticancer therapy after
350 lockdown ending (from May to October 2020). Of these indicators, 14 (50%) reported an increase in
351 the number of treatments (in UK and France).


352

353 Regarding “delay in treatment”, a total of 42 indicators from 18 articles
354 [39,52,72,77,81,89,91,92,96,97,99,101,138,142–146] were identified. Of those, 18 (43%) reported an
355 increasing trend in waiting time to treatment, namely in France, Portugal, Canada, US, and Italy.
356 Sixteen indicators (38%) signalled stable waiting times and 8 (19%) a reduction in time to treatment.
357 Twenty-one surveys [58,70,84–86,88,108,109,114,117,132–134,141,147–153], 2 studies using
358 administrative data and surveys [121,138] and 1 prospective study [117] reported on delays in cancer
359 treatment. From those, eleven articles were international studies. All have reported delays or
360 interruptions on different aspects of cancer treatment, namely in Canada, France, Germany, Italy,
361 Netherlands, US, and UK.

362 Fifty articles reported on “changes in treatment”, resulting in 304 indicators collated. A total of 106
363 indicators (19 articles [50,52,65,75,77,90,96–98,101,102,106,118,121,135,137,138,142,154]) were
364 collected from administrative data, 13 indicators from registry data [134,138] and 185 were survey-
365 base information [13,46,58,70,78,85,88,113–116,126,130,141,145,148–151,155–159]. Changes in
366 treatment are summarized in Fig. 3.


367

Treatment changes reported (304 indicators from 50 articles)




368

Change in treatment performed (n=195 indicators)



369

Change in treatment "protocol" (n=40)



385 **Fig. 3 – Treatment changes reported in the articles.** IV: intravenous; CRT: chemotherapy.

386

387 Modifications in treatment were reported in 195 (64%) of indicators. The most frequent changes in
388 treatment were in surgical procedures (n=56 indicators, 29%), radiation-specific changes (n=55
389 indicators, 28%) and change of original protocol of chemotherapy (n=45 indicators, 23%).
390 Modifications documented in surgical procedures were a decrease in use of laparoscopic surgery
391 together with an increase of open or radical surgery, an increase in stoma formation rate, and a decrease
392 of immediate breast reconstruction rate in breast cancer patients. The radiation-specific care variations
393 identified were radiotherapy hypofractionation, treatment disruptions, increase in short-course
394 treatments, and physicians being less likely to prescribe adjuvant radiotherapy.

395 Treatment “protocol” changes were reported by 40 indicators. The most frequent change was
396 performing surgery without neoadjuvant chemotherapy (Fig. 3).

397

398 A total of 12 indicators from 4 articles [42,55,93,99] reported on the “number of visits and admissions”
399 of cancer patients to the hospital. Of these indicators, 10 (83%) signalled a decreasing trend. Two
400 international surveys [55,85] to health professionals have also disclosed a decrease in the number of
401 oncology unit hospitalizations.


402 Regarding the “utilization of telemedicine”, 4 indicators were identified from 4 articles
403 [68,86,103,152]. Fourteen surveys [13,58,70,109,112–115,134,141,145,149,152,157] provided
404 information on telemedicine use, from which ten were international studies. Three were patients’
405 surveys. All the survey-based information and quantitative indicators reported an increase in the use
406 of telehealth to provide cancer care. One article [160] assessed patient and providers’ satisfaction
407 regarding the use of telemedicine in rehabilitation of cancer patients. The proportion of patients that
408 provided good feedback ranged from 63% to 84%, and the physicians’ perspective was also
409 satisfactory, ranging from 66% to 83% of physicians reporting positive feedback. Four international
410 surveys [115,141,145,150] addressed the implementation of virtual multidisciplinary tumor boards,
411 showing a marked increase in the use of web-based platforms.

412 Two main outcomes were addressed in the included articles: “procedures and surgical outcome
413 measures” and “mortality”. Fifteen indicators from 8 articles [93,97–103] conveyed information
414 regarding procedures’ outcomes. From these indicators, 11 (73%) showed similar complication rates.
415 One Italian survey [127] has also documented a stable number of complications after esophageal
416 resections.

417 With respect to mortality in cancer patients, 24 indicators were identified from 4 articles. Twenty of
418 these indicators resulted from one Portuguese study [105], the other 3 indicators showed a stable
419 postoperative death rate in patients with head and neck cancer (France) [102], and a stable in-hospital
420 mortality rate for orthopedic tumors at the traumatology department (Germany) [123]. One Turkish
421 study [100] documented increased mortality in occlusive colorectal cancers patients.

422 The trends of the indicators are summarized in Fig. 4.

423



424

425 **Fig. 4 – Number of cancer care indicators and trends per category (%), according to the cancer care pathway**

426 Discussion

427 In this study, we performed a scoping review to identify the indicators used in the literature to measure
428 the impact of the COVID-19 pandemic on the cancer care pathway from January to June 2020, and the
429 changes in the quality of care signalled by these indicators. We identified a total of 135 articles, with
430 a total of 917 quantitative indicators, reporting on 94 countries. Changes in the quality of care are
431 spread across the care pathway. This performance information suggests capacity constraints, it shows
432 quick adaptations and innovations in cancer management. If collected in near-real-time and processed
433 into actionable information, it would allow monitoring changes in care during the current pandemic
434 and in future events more efficiently, supporting timely and adequate responses.

435 Our findings signal a major impact on the diagnosis of cancer: a decreasing trend in the number of
436 screenings, diagnostic procedures, and, consequently, in the number of cancer diagnoses, resulting in
437 increasing screening detection rates, and delays in diagnostic care. These result from the reduction of
438 screening programs [4], the cancelation of elective procedures [22], and patients' avoidance of going
439 to healthcare facilities [161,162]. Previous studies documented the decreasing number of primary care
440 consultations for a wide range of clinical conditions [163,164] and a relevant fall in new cancer
441 diagnoses in primary care [76].

442 Trends regarding cancer staging at diagnosis portray a mixed picture. The reduction in the number of
443 elective diagnostic procedures could explain stage-shifts in cancer presentation. We also found an
444 increasing trend in the proportion of urgent/emergent cancer referrals and in the proportion of emergent
445 procedures, as well as evidence of patients presenting with a more severe clinical condition to the
446 hospital than before the pandemic. These trends suggest patients with advanced-stage cancers
447 continued to seek care. It could also signal those patients waited longer before receiving care, with
448 potential deleterious outcomes. These results highlight the need to closely monitor the impact of the
449 COVID-19 pandemic on shifts in cancer staging at diagnosis and the relevance of collecting this data
450 systematically, which is a reality only in a few OECD countries, such as the Netherlands and Slovenia
451 [165].

452 With respect to treatment, about 40% of the indicators reporting on waiting times to treatment signalled
453 an increasing trend, we observe a decreasing trend in the volume of the three modalities of cancer
454 treatment, and a large number and diversity of information reporting on treatment changes. These
455 results reveal the remarkable influence of the pandemic on patterns of cancer care in the first half of
456 2020. These changes result from postponements of care decided by physicians to decrease patients'
457 exposure to hospitals [113], switch to audio- or video-consultations, and deferrals and treatment
458 modifications guided by updated recommendations by many medical societies [11,12]. Almost two-
459 thirds of the indicators reported changes in treatment, which shows that providers have quickly adapted
460 their care practices, which strengthens the argument for the need for monitoring closely these changes.
461 While some of these care modifications could be learning opportunities for the future, this information
462 should be standardised, transparent, and timely, allowing to appraise the modifications in care provided
463 during crises regarding access, quality, and outcomes.

464 The increase in telemedicine utilization we report is a generalized trend across a range of medical
465 specialties [4] and it constitutes a hallmark of the innovation triggered by this pandemic. Albeit the
466 positive feedback by physicians and patients we report, telehealth risks to increase inequalities in
467 access to care [166,167].

468 Short-term oncological outcomes were addressed by a few indicators and are reported as being stable,
469 which is in line with a recent international cohort study including 61 countries and 15 tumor types
470 [22]. However, deferred care will most likely lead to worse long-term outcomes, which needs to be
471 monitored. Attempts to quantify this impact were developed, for instance, by a British nation-wide
472 modelling study where the authors estimated a total of 59 204–63 229 additional years of life lost
473 attributed to four major cancers [168], compared with pre-pandemic data.

474 Previous works addressed the impact of the COVID-19 pandemic on regional or national settings
475 [5,50], on specific cancers [5,6,169], specific stages of the care pathway [54], or treatment modalities
476 [22]. This scoping review provides a summary of cancer care performance indicators, concerning
477 various diseases, from early detection to the treatment phase of the care pathway, within OECD
478 countries. Additionally, we report changes in the quality of cancer care based on indicators' trends,

479 from January to June 2020, which constitutes an innovative approach to assess changes in healthcare
480 performance.

481 Our study has some limitations. The heterogeneity of study designs, populations, diseases, indicators,
482 and indicators' definitions do not allow application of a meta-analysis approach and quantifying the
483 real impact of the pandemic on cancer care. We also recognize potential bias that could arise from the
484 inclusion of survey data, which rely on what respondents recall and report. However, a relevant number
485 of surveys were conducted by international societies and networks of providers, which allows for the
486 collection of credible information regarding changes in care. Surveys also show how medical societies
487 and countries were unable to obtain these data using current health information systems and data
488 structures. We acknowledge the patients' perspective is not comprehensive since only a few surveys
489 included patient-reported outcomes and experiences of care measures. The cancer care pathway is not
490 complete in this study, as it did not address primary prevention, rehabilitation, and palliative care.
491 Nonetheless, we provide a thorough overview of the cancer care pathway, from diagnosis to outcomes.

492 The distribution of studies per country is not homogenous in this study, which does not allow to
493 generalize these trends to all included countries or to fully assess disparities in cancer care between
494 OECD countries. Care inequalities could have been exacerbated during this pandemic, which needs to
495 be further studied regarding cancer care.

496 The COVID-19 pandemic keeps evolving until the present time and postponing of care was reported
497 in some countries by the end of 2021 and the beginning of 2022 [170,171], which means that this
498 impact is adding up. Figures concerning new COVID-19 cases, mortality, and vaccination coverage,
499 are presented daily to the public since the beginning of 2020. Additional and considerable efforts are
500 needed to expose the effects caused by this pandemic in non-COVID-19 care, and some of the
501 indicators we present could be useful to convey that message.

502 As new waves keep evolving, it is crucial to monitor performance indicators, such as shifts in cancer
503 staging or worsening of outcomes, closely and promptly. Also, the link between structure, process, and
504 (short- and long-term) outcome indicators should be undertaken to allow an accurate and timely

505 evaluation of the changes in the care provided during crises (and in regular times). Tools like the “Time
506 to Act Data Navigator” [172] developed by the European Cancer Organization and the “Global Cancer
507 Observatory” [173] signal the ambition to address this lack of standardised and regular collection of
508 data and indicators. Within the scope of Europe’s Beating Cancer Plan, the European Cancer
509 Inequalities Registry [20] aims to monitor inequalities across Europe, by providing reliable data on
510 cancer prevention and care.

511

512 **Conclusion**

513 Our results provide a summary of performance indicators used in the literature to assess the cancer
514 care pathway from January 2020 to June 2020, and the changes in the quality of care signalled by these
515 indicators. This study shows that health systems struggled to ensure the continuity in the quality of
516 care to cancer patients in OECD countries. This information could inform on the bottlenecks of the
517 cancer care pathway and contribute to identifying disparities between and within countries, as well as
518 moments for intervention during the evolving pandemic and in future crises. Further research and
519 investment are necessary to generate system-wide oriented intelligence and strengthen data
520 infrastructures worldwide, to support timely and adequate health policy responses.

521

522 **Acknowledgements**

523 The authors wish to thank Wichor Bramer from the Erasmus MC Medical Library for developing and
524 updating the search strategies used in this study.

525

526 **Funding**

527 This research received no specific grant from any funding agency in the public, commercial, or not-
528 for-profit sectors.

529

530 **Conflict of interest**

531 None declared.

532

533 **Ethics approval and consent to participate**

534 Not required.

535

536 **Data availability**

537 The data underlying this article are available in Zenodo.org, at
538 <https://doi.org/10.5281/zenodo.6129839>.

539

540 **Authors' contributions**

541 All authors contributed to conceptualize the study. ASC and MdL performed the data collection. ASC
542 performed the data analysis and drafted the article. All authors provided feedback and contributed to
543 revising the manuscript. All authors approved the final version of the manuscript.

544 **References**

545

546 1. World Health Organization. A year without precedent: WHO's COVID-19 response [Internet].

547 [cited 2022 Feb 11]. Available from: [https://www.who.int/news-room/spotlight/a-year-without-](https://www.who.int/news-room/spotlight/a-year-without-precedent-who-s-covid-19-response)

548 precedent-who-s-covid-19-response

549 2. World Health Organization. Pulse survey on continuity of essential health services during the

550 COVID-19 pandemic - Key informant findings from 135 countries, territories and areas - Quarter 1

551 2021 Reporting period: 3 months preceding date of survey submission [Internet]. [cited 2022 Jan 18].

552 Available from: [https://www.who.int/docs/default-source/coronaviruse/finalupdate_22-april-](https://www.who.int/docs/default-source/coronaviruse/finalupdate_22-april-2021_summary-ppt_ehs-pulse-survey_second-round.pdf?sfvrsn=a965e121_8)

553 2021_summary-ppt_ehs-pulse-survey_second-round.pdf?sfvrsn=a965e121_8

554 3. World Health Organization. Health Topics - Cancer [Internet]. [cited 2022 Jan 25]. Available from:

555 https://www.who.int/health-topics/cancer#tab=tab_1

556 4. OECD. Health at a Glance 2021: OECD Indicators, OECD Publishing, Paris. [Internet]. 2021.

557 Available from: <https://doi.org/10.1787/ae3016b9-en>.

558 5. Eijkelboom AH, de Munck L, Vrancken Peeters M-JTFD, Broeders MJM, Strobbe LJA, Bos

559 MEMM, et al. Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast

560 cancer in the Netherlands: a population-based study. *J Hematol Oncol*. 2021;14:64.

561 6. Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, et al.

562 Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution

563 of colorectal cancers in the Netherlands. *Eur J Cancer*. 2022;161:38–43.

564 7. Amador M, Matias-Guiu X, Sancho-Pardo G, Contreras Martinez J, de la Torre-Montero JC,

565 Peñuelas Saiz A, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain.

566 *ESMO Open*. 2021;6:100157.

- 567 8. Peacock HM, Tambuyzer T, Verdoodt F, Calay F, Poirel HA, De Schutter H, et al. Decline and
568 incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long,
569 population-level analysis. *ESMO Open*. 2021;6:100197.
- 570 9. Skovlund CW, Friis S, Dehlendorff C, Nilbert MC, Mørch LS. Hidden morbidities: drop in cancer
571 diagnoses during the COVID-19 pandemic in Denmark. *Acta Oncol*. 2021;60:20–3.
- 572 10. Burki TK. Cancer guidelines during the COVID-19 pandemic. *Lancet Oncol*. 2020;21:629–30.
- 573 11. BASO~The Association for Cancer Surgery BASO Guidance. Strategy for Cancer Surgery
574 sustainability and recovery in the COVID 19 pandemic. [Internet]. [cited 2021 Dec 9]. Available from:
575 https://baso.org.uk/media/99217/baso_guidance_for_cancer_surgery_9th_april_2020_v7.pdf
- 576 12. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, et al. Managing cancer
577 patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*.
578 2020;31:1320–35.
- 579 13. Chazan G, Franchini F, Alexander M, Banerjee S, Mileskin L, Blinman P, et al. Impact of
580 COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
581 *ESMO Open*. 2020;5:e001090.
- 582 14. United Nations - Department of Economic and Social Affairs. Sustainable Development. The 17
583 Goals. [Internet]. [cited 2022 Jan 11]. Available from: <https://sdgs.un.org/goals>
- 584 15. World Health Organization. World Health Assembly 70. Cancer prevention and control in the
585 context of an integrated approach. [Internet]. 2017 [cited 2022 Jan 11]. Available from:
586 https://apps.who.int/iris/bitstream/handle/10665/275676/A70_R12-en.pdf?sequence=1&isAllowed=y
- 587 16. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, et al. Cancer
588 survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*.
589 2008;9:730–56.

- 590 17. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, et al. Global surveillance of
591 cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-
592 based registries in 67 countries (CONCORD-2). *The Lancet*. 2015;385:977–1010.
- 593 18. European Commission. Public health - Non-communicable diseases - Cancer. [Internet]. [cited 2022
594 Jan 17]. Available from: https://ec.europa.eu/health/non-communicable-diseases/cancer_en
- 595 19. European Commission. Communication from the Commission to the European Parliament and the
596 Council - Europe's Beating Cancer Plan. [Internet]. 2021 [cited 2022 Jan 11]. Available from:
597 [https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-](https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf)
598 [plan_en.pdf](https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf)
- 599 20. European Commission. European Cancer Inequalities Registry. [Internet]. [cited 2022 Jan 24].
600 Available from: <https://cancer-inequalities.jrc.ec.europa.eu/>
- 601 21. European Commission. EU Science Hub. Launch of the EC Knowledge Centre on Cancer. [Internet].
602 [cited 2022 Jan 11]. Available from: [https://ec.europa.eu/jrc/en/event/conference/launch-ec-](https://ec.europa.eu/jrc/en/event/conference/launch-ec-knowledge-centre-cancer)
603 [knowledge-centre-cancer](https://ec.europa.eu/jrc/en/event/conference/launch-ec-knowledge-centre-cancer)
- 604 22. Glasbey J, Ademuyiwa A, Adisa A, AlAmeer E, Arnaud AP, Ayasra F, et al. Effect of COVID-19
605 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international,
606 prospective, cohort study. *Lancet Oncol*. 2021;22:1507–17.
- 607 23. Blay JY, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D, et al. Delayed care for patients with
608 newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. *ESMO*
609 *Open*. 2021;6:100134.
- 610 24. Kirchberg J, Rentsch A, Klimova A, Vovk V, Hempel S, Folprecht G, et al. Influence of the First
611 Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. *Front*
612 *Public Health*. 2021;9:750479.

- 613 25. Kringos D, Carinci F, Barbazza E, Bos V, Gilmore K, Groene O, et al. Managing COVID-19
614 within and across health systems: why we need performance intelligence to coordinate a global
615 response. *Health Res Policy Syst.* 2020;18:80.
- 616 26. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res*
617 *Methodol.* 2005;8:19–32.
- 618 27. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement*
619 *Sci.* 2010;5:69.
- 620 28. Tolonen H, Reinikainen J, Koponen P, Elonheimo H, Palmieri L, Tjihuis MJ, et al. Cross-national
621 comparisons of health indicators require standardized definitions and common data sources. *Arch*
622 *Public Health.* 2021;79:208.
- 623 29. Lockwood C, dos Santos KB, Pap R. Practical Guidance for Knowledge Synthesis: Scoping
624 Review Methods. *Asian Nurs Res.* 2019;13:287–94.
- 625 30. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or
626 scoping review? Guidance for authors when choosing between a systematic or scoping review
627 approach. *BMC Med Res Methodol.* 2018;18:143.
- 628 31. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for
629 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–73.
- 630 32. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
631 systematic reviews. *Syst Rev.* 2016;5:210.
- 632 33. Minucci A, Scambia G, Santonocito C, Concolino P, Urbani A. BRCA testing in a genomic
633 diagnostics referral center during the COVID-19 pandemic. *Mol Biol Rep.* 2020;47:4857–60.
- 634 34. Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, et al. BRCA testing
635 delay during the COVID-19 pandemic: How to act? *Mol Biol Rep.* 2021;48:983–7.

- 636 35. London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19
637 Pandemic on Cancer-Related Patient Encounters. *JCO Clin Cancer Inform.* 2020;657–65.
- 638 36. Henderson LM, Benefield T, Bosemani T, Long JM, Rivera MP. Impact of the COVID-19
639 Pandemic on Volumes and Disparities in Lung Cancer Screening. *Chest.* 2021;160:379–82.
- 640 37. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh Q-D. Cancer Screening Tests
641 and Cancer Diagnoses During the COVID-19 Pandemic. *JAMA Oncol.* 2021;7:458.
- 642 38. Miller MJ, Xu L, Qin J, Hahn EE, Ngo-Metzger Q, Mittman B, et al. Impact of COVID-19 on
643 Cervical Cancer Screening Rates Among Women Aged 21–65 Years in a Large Integrated Health Care
644 System — Southern California, January 1–September 30, 2019, and January 1–September 30, 2020.
645 *MMWR Morb Mortal Wkly Rep.* 2021;70:109–13.
- 646 39. Suárez J, Mata E, Guerra A, Jiménez G, Montes M, Arias F, et al. Impact of the COVID-19
647 pandemic during Spain’s state of emergency on the diagnosis of colorectal cancer. *J Surg Oncol.*
648 2021;123:32–6.
- 649 40. Maganty A, Yu M, Anyaeche VI, Zhu T, Hay JM, Davies BJ, et al. Referral pattern for urologic
650 malignancies before and during the COVID-19 pandemic. *Urol Oncol Semin Orig Investig.*
651 2021;39:268–76.
- 652 41. Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, et al. Two-month stop in
653 mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront
654 treatment in the COVID era. *ESMO Open.* 2021;6:100055.
- 655 42. Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on Cancer
656 Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. *JCO*
657 *Clin Cancer Inform.* 2020;1059–71.
- 658 43. Song H, Bergman A, Chen AT, Ellis D, David G, Friedman AB, et al. Disruptions in preventive
659 care: Mammograms during the COVID-19 pandemic. *Health Serv Res.* 2021;56:95–101.

- 660 44. Yin K, Singh P, Drohan B, Hughes KS. Breast imaging, breast surgery, and cancer genetics in the
661 age of COVID-19. *Cancer*. 2020;126:4466–72.
- 662 45. Nyante, S. J., Benefield, T. S., Kuzmiak, C. M., Earnhardt, K., Pritchard, M., Henderson, L. M.
663 Population-level impact of coronavirus disease 2019 on breast cancer screening and diagnostic
664 procedures. *Cancer*. 2021;127:2111–21.
- 665 46. Rocco N, Montagna G, Di Micco R, Benson J, Criscitiello C, Chen L, et al. The Impact of the
666 COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future
667 Perspectives. *The Oncologist*. 2021;26:e66–77.
- 668 47. D’Ovidio V, Lucidi C, Bruno G, Lisi D, Miglioresi L, Bazuro ME. Impact of COVID-19 Pandemic
669 on Colorectal Cancer Screening Program. *Clin Colorectal Cancer*. 2021;20:e5–11.
- 670 48. Furnari M, Eusebi LH, Savarino E, Petruzzellis C, Esposito G, Maida M, et al. Effects of SARS-
671 CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. *Gut*.
672 2021;70:1241–3.
- 673 49. John A, Mian M, Sreedharan S, Kahokehr AA. The impact of the coronavirus disease 2019
674 pandemic on elective urological procedures in Australia. *Asian J Urol*. 2022;9:35–41.
- 675 50. Kiziltan G, Tumer CBK, Ozaslan C, Guler OC. Effects of COVID-19 pandemics in a Breast unit.
676 *Eur J Cancer*. 2020;138:S116.
- 677 51. O’Connor E, O’Dowd G, Phelan S. Impact of COVID-19 on small biopsy diagnostic procedures
678 and cancer resection surgeries in the North-West of Ireland. *J Clin Pathol*. 2021;jclinpath-2021-
679 207425.
- 680 52. Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, et al. Impact of COVID-
681 19 on the management of hepatocellular carcinoma in a high-prevalence area. *JHEP Rep*.
682 2021;3:100199.

- 683 53. Qua Quarini E, Saltalamacchia G, Presti D, Caldana G, Tibollo V, Malovini A, et al. Impact of
684 COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic
685 in Lombardy (Italy). *Cancers*. 2020;12:2941.
- 686 54. Lantinga MA, Theunissen F, ter Borg PCJ, Bruno MJ, Ouwendijk RJT, Siersema PD, et al. Impact
687 of the COVID-19 pandemic on gastrointestinal endoscopy in the Netherlands: analysis of a prospective
688 endoscopy database. *Endoscopy*. 2021;53:166–70.
- 689 55. Penel N, Hammoudi A, Marliot G, De Courreges A, Cucchi M, Mirabel X, et al. Major impact of
690 COVID-19 national containment on activities in the French northern comprehensive cancer center.
691 *Med Oncol*. 2021;38:28.
- 692 56. Markar SR, Clarke J, Kinross J. Practice patterns of diagnostic upper gastrointestinal endoscopy
693 during the initial COVID-19 outbreak in England. *Lancet Gastroenterol Hepatol*. 2020;5:804–5.
- 694 57. Wassie MM, Agaciak M, Cock C, Bampton P, Young GP, Symonds EL. The impact of coronavirus
695 disease 2019 on surveillance colonoscopies in South Australia. *JGH Open*. 2021;5:486–92.
- 696 58. CRC COVID Research Collaborative. The impact of the COVID-19 pandemic on colorectal cancer
697 service provision. *Br J Surg*. 2020;107:e521-2.
- 698 59. Rutter MD, Brookes M, Lee TJ, Rogers P, Sharp L. Impact of the COVID-19 pandemic on UK
699 endoscopic activity and cancer detection: a National Endoscopy Database Analysis. *Gut*.
700 2021;70:537–43.
- 701 60. Zadnik V, Mihor A, Tomsic S, Zagar T, Bric N, Lokar K, et al. Impact of COVID-19 on cancer
702 diagnosis and management in Slovenia – preliminary results. *Radiol Oncol*. 2020;54:329–34.
- 703 61. Uyl-de Groot CA, Schuurman MS, Huijgens PC, Praagman J. Fewer cancer diagnoses during the
704 COVID-19 epidemic according to diagnosis, age and region. *TSG - Tijdschr Voor*
705 *Gezondheidswetenschappen*. 2021;99:1–8.

- 706 62. Barruscotti S, Giorgini C, Brazzelli V, Vassallo C, Michelerio A, Klersy C, et al. A significant
707 reduction in the diagnosis of melanoma during the COVID-19 lockdown in a third-level center in the
708 Northern Italy. *Dermatol Ther* [Internet]. 2020 [cited 2022 Feb 17];33. Available from:
709 <https://onlinelibrary.wiley.com/doi/10.1111/dth.14074>
- 710 63. Ferrara G, De Vincentiis L, Ambrosini-Spaltro A, Barbareschi M, Bertolini V, Contato E, et al.
711 Cancer Diagnostic Delay in Northern and Central Italy During the 2020 Lockdown Due to the
712 Coronavirus Disease 2019 Pandemic. *Am J Clin Pathol*. 2021;155:64–8.
- 713 64. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly
714 Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. *JAMA*
715 *Netw Open*. 2020;3:e2017267.
- 716 65. Kiong KL, Guo T, Yao CMKL, Gross ND, Hanasono MM, Ferrarotto R, et al. Changing practice
717 patterns in head and neck oncologic surgery in the early COVID -19 era. *Head Neck*. 2020;42:1179–
718 86.
- 719 66. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali SZ, Baloch ZW, Bellevicine C, et al. Global impact
720 of the COVID-19 pandemic on cytopathology practice: Results from an international survey of
721 laboratories in 23 countries. *Cancer Cytopathol*. 2020;128:885–94.
- 722 67. Ricci F, Fania L, Paradisi A, Di Lella G, Pallotta S, Sobrino L, et al. Delayed melanoma diagnosis
723 in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19
724 lockdown. *J Eur Acad Dermatol Venereol* [Internet]. 2020 [cited 2022 Feb 17];34. Available from:
725 <https://onlinelibrary.wiley.com/doi/10.1111/jdv.16874>
- 726 68. De Vincentiis L, Mariani MP, Ferrara G. Dermatologic Oncology and Histopathology at a
727 Secondary Care Centre During the Coronavirus Disease 2019 Pandemic. *Am J Dermatopathol*.
728 2021;43:160–2.

- 729 69. Suh-Burgmann EJ, Alavi M, Schmittziel J. Endometrial Cancer Detection During the Coronavirus
730 Disease 2019 (COVID-19) Pandemic. *Obstet Gynecol.* 2020;136:842–3.
- 731 70. Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, et al. Impact of the
732 SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a
733 report from the Italian Association for Neuroendocrine Tumors (Itanet). *J Endocrinol Invest.*
734 2021;44:989–94.
- 735 71. Fernández Canedo MI, de Troya Martín M, Rivas Ruíz F. Impacto de la pandemia SARS-CoV-2
736 en el diagnóstico precoz del melanoma. *Med Clínica.* 2021;156:356–7.
- 737 72. Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and impact on breast
738 cancer diagnoses: what happened in England in the first half of 2020. *Br J Cancer.* 2021;124:710–2.
- 739 73. Shannon AB, Sharon CE, Straker RJ, Miura JT, Ming ME, Chu EY, et al. The impact of the
740 COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution
741 experience. *J Am Acad Dermatol.* 2021;84:1096–8.
- 742 74. Dinmohamed AG, Cellamare M, Visser O, de Munck L, Elferink MAG, Westenend PJ, et al. The
743 impact of the temporary suspension of national cancer screening programmes due to the COVID-19
744 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. *J Hematol OncolJ*
745 *Hematol Oncol.* 2020;13:147.
- 746 75. Wang H, Elsheikh M, Gilmour K, Cohen V, Sagoo MS, Damato B, et al. Impact of COVID-19
747 pandemic on eye cancer care in United Kingdom. *Br J Cancer.* 2021;124:1357–60.
- 748 76. Jacob L, Loosen SH, Kalder M, Luedde T, Roderburg C, Kostev K. Impact of the COVID-19
749 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany. *Cancers.*
750 2021;13:408.

- 751 77. Van Haren RM, Delman AM, Turner KM, Waits B, Hemingway M, Shah SA, et al. Impact of the
752 COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer. *J Am Coll*
753 *Surg.* 2021;232:600–5.
- 754 78. Price SJ, Joannides A, Plaha P, Afshari FT, Albanese E, Barua NU, et al. Impact of COVID-19
755 pandemic on surgical neuro-oncology multi-disciplinary team decision making: a national survey
756 (COVID-CNSMDT Study). *BMJ Open.* 2020;10:e040898.
- 757 79. Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM,
758 et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. *Lancet Oncol.*
759 2020;21:750–1.
- 760 80. Valenti M, Pavia G, Gargiulo L, Facheris P, Nucca O, Mancini L, et al. Impact of delay in follow-
761 up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub
762 hospital. *Int J Dermatol.* 2021;60:860–3.
- 763 81. Kiong KL, Diaz EM, Gross ND, Diaz EM, Hanna EY. The impact of COVID-19 on head and neck
764 cancer diagnosis and disease extent. *Head Neck.* 2021;43:1890–7.
- 765 82. Marson JW, Maner BS, Harding TP, Meisenheimer J, Solomon JA, Leavitt M, et al. The magnitude
766 of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers. *J Am*
767 *Acad Dermatol.* 2021;84:1100–3.
- 768 83. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, Ali S, Baloch Z, Bongiovanni M, et al. COVID-19
769 Pandemic effect on Cytopathology Practice: Results from 23 Laboratories in 11 Countries. *J Am Soc*
770 *Cytopathol.* 2020;9:S51.
- 771 84. Torzilli G, Viganò L, Galvanin J, Castoro C, Quagliuolo V, Spinelli A, et al. A Snapshot of Elective
772 Oncological Surgery in Italy During COVID-19 Emergency: Pearls, Pitfalls, and Perspectives. *Ann*
773 *Surg.* 2020;272:e112–7.

- 774 85. Santoro GA, Grossi U, Murad-Regadas S, Nunoo-Mensah JW, Mellgren A, Di Tanna GL, et al.
775 DELayed COloRectal cancer care during COVID-19 Pandemic (DECOR-19): Global perspective from
776 an international survey. *Surgery*. 2021;169:796–807.
- 777 86. Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the
778 COVID-19 pandemic. *Breast Cancer Res Treat*. 2020;184:249–54.
- 779 87. Krug S, Garbe J, König S, Ungewiss H, Michl P, Rinke A, et al. Professional Assessment of the
780 Impact of COVID-19 on Handling NET Patients. *J Clin Med*. 2020;9:3633.
- 781 88. Boyle JM, Kuryba A, Blake HA, Aggarwal A, Meulen J, Walker K, et al. The impact of the first
782 peak of the COVID-19 pandemic on colorectal cancer services in England and Wales: A national
783 survey. *Colorectal Dis*. 2021;23:1733–44.
- 784 89. Andrew TW, Alrawi M, Lovat P. Reduction in skin cancer diagnoses in the UK during the COVID-
785 19 pandemic. *Clin Exp Dermatol*. 2021;46:145–6.
- 786 90. Nolan, G. S., Dunne, J. A., Kiely, A. L., Pritchard Jones, R. O., Gardiner, M, Jain, A. The effect
787 of the COVID-19 pandemic on skin cancer surgery in the United Kingdom: a national, multi-centre,
788 prospective cohort study and survey of Plastic Surgeons. *J Br Surg*. 2020;107:e598–600.
- 789 91. Taylor R, Omakobia E, Sood S, Glore RJ. The impact of coronavirus disease 2019 on head and
790 neck cancer services: a UK tertiary centre study. *J Laryngol Otol*. 2020;134:684–7.
- 791 92. Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J, et al. Impact of the COVID-19
792 pandemic on the detection and management of colorectal cancer in England: a population-based study.
793 *Lancet Gastroenterol Hepatol*. 2021;6:199–208.
- 794 93. Kvolik Pavić A, Zubčić V, Kvolik S. Workload changes during the COVID-19 pandemic and
795 effects on the flow of cancer patients in the Maxillofacial Surgery Department. *Med Glas Ljek Komore*
796 *Zenicko-Doboj Kantona* [Internet]. 2021 [cited 2022 Feb 17]; Available from:
797 <https://doi.org/10.17392/1308-21>

- 798 94. Vissio E, Falco EC, Collemi G, Borella F, Papotti M, Scarmozzino A, et al. Impact of COVID-19
799 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a
800 tertiary referral hospital in Northwestern Italy. *J Surg Oncol*. 2021;123:24–31.
- 801 95. Weston GK, Jeong HS, Mu EW, Polsky D, Meehan SA. Impact of COVID-19 on melanoma
802 diagnosis. *Melanoma Res*. 2021;31:280–1.
- 803 96. Gosset M, Gal J, Schiappa R, Dejode M, Fouché Y, Alazet F, et al. Impact de la pandémie de
804 COVID-19 sur les prises en charge pour cancer du sein et gynécologique. *Bull Cancer (Paris)*.
805 2021;108:3–11.
- 806 97. Veiga J, Amante S, Costa NV, Luz JH, Gomes FV, Coimbra É, et al. The Covid-19 Pandemic
807 Constraints May Lead to Disease Progression for Patients with Liver Cancer Scheduled to Receive
808 Locoregional Therapies: Single-Centre Retrospective Analysis in an Interventional Radiology Unit.
809 *Cardiovasc Intervent Radiol*. 2021;44:669–72.
- 810 98. Leung E, Pervaiz Z, Lowe-Zinola J, Cree S, Kwong A, Marriott N, et al. Maintaining surgical care
811 delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological
812 cancer centre. *Gynecol Oncol*. 2021;160:649–54.
- 813 99. Rodrigues-Pinto E, Ferreira-Silva J, Fugazza A, Capogreco A, Repici A, Everett S, et al. Upper
814 gastrointestinal stenting during the SARS-CoV-2 outbreak: impact of mitigation measures and risk of
815 contamination for patients and staff. *Endosc Int Open*. 2021;09:E76–86.
- 816 100. Ferahman S, Dönmez T, Sürek A, Aydın H, Gümüsoğlu AY, Karabulut M. Effects of COVID-
817 19 Outbreak on Emergency Surgeries for Occlusive Colorectal Cancers. *Turk J Colorectal Dis*.
818 2020;30:237–45.
- 819 101. Vanni G, Tazzioli G, Pellicciaro M, Materazzo M, Paolo O, Cattadori F, et al. Delay in Breast
820 Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
821 *Anticancer Res*. 2020;40:7119–25.

- 822 102. Laccourreya O, Mirghani H, Evrard D, Bonnefont P, Brugel L, Tankere F, et al. Impact of the
823 first month of Covid-19 lockdown on oncologic surgical activity in the Ile de France region university
824 hospital otorhinolaryngology departments. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2020;137:273–
825 6.
- 826 103. Filipe MD, van Deukeren D, Kip M, Doeksen A, Pronk A, Verheijen PM, et al. Effect of the
827 COVID-19 Pandemic on Surgical Breast Cancer Care in the Netherlands: A Multicenter Retrospective
828 Cohort Study. *Clin Breast Cancer.* 2020;20:454–61.
- 829 104. Purushotham A, Roberts G, Haire K, Dodkins J, Harvey-Jones E, Han L, et al. The impact of
830 national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients.
831 *ecancermedalscience* [Internet]. 2021 [cited 2022 Feb 17];15. Available from:
832 [https://ecancer.org/en/journal/article/1180-the-impact-of-national-non-pharmaceutical-interventions-](https://ecancer.org/en/journal/article/1180-the-impact-of-national-non-pharmaceutical-interventions-lockdowns-on-the-presentation-of-cancer-patients)
833 [lockdowns-on-the-presentation-of-cancer-patients](https://ecancer.org/en/journal/article/1180-the-impact-of-national-non-pharmaceutical-interventions-lockdowns-on-the-presentation-of-cancer-patients)
- 834 105. Morais S, Antunes L, Rodrigues J, Fontes F, Bento MJ, Lunet N. The impact of the COVID-19
835 pandemic on the short-term survival of patients with cancer in Northern Portugal. *Int J Cancer.*
836 2021;149:287–96.
- 837 106. Manso L, De Velasco G, Paz-Ares L. Impact of the COVID-19 outbreak on cancer patient flow
838 and management: experience from a large university hospital in Spain. *ESMO Open.* 2020;5:e000828.
- 839 107. Rogado J, Obispo B, Gullón P, Lara MÁ. Impact of the COVID-19 pandemic in cancer diagnosis
840 in the first and second waves in one of the most affected cancer areas in the city of Madrid (Spain). *Int*
841 *J Cancer.* 2021;148:1794–5.
- 842 108. Oderda M, Callaris G, Falcone M, Fasolis G, Muto G, Oderda G, et al. How uro-oncology has
843 been affected by COVID-19 emergency? Data from Piedmont/Valle d’Aosta Oncological Network,
844 Italy. *Urol J.* 2021;88:3–8.

- 845 109. Slotman BJ, Lievens Y, Poortmans P, Cremades V, Eichler T, Wakefield DV, et al. Effect of
846 COVID-19 pandemic on practice in European radiation oncology centers. *Radiother Oncol.*
847 2020;150:40–2.
- 848 110. Park JY, Lee YJ, Kim T, Lee CY, Kim HI, Kim J-H, et al. Collateral effects of the coronavirus
849 disease 2019 pandemic on lung cancer diagnosis in Korea. *BMC Cancer.* 2020;20:1040.
- 850 111. Zuliani S, Zampiva I, Tregnago D, Casali M, Cavaliere A, Fumagalli A, et al. Organisational
851 challenges, volumes of oncological activity and patients' perception during the severe acute respiratory
852 syndrome coronavirus 2 epidemic. *Eur J Cancer.* 2020;135:159–69.
- 853 112. Gordan, L. N., Weidner, S. Impact of the COVID-19 pandemic on specialty community practices:
854 an oncology perspective. *Am J Manag Care.* 2020;26:SP333–5.
- 855 113. Gill S, Hao D, Hirte H, Campbell A, Colwell B. Impact of COVID-19 on Canadian Medical
856 Oncologists and Cancer Care: Canadian Association of Medical Oncologists Survey Report. *Curr*
857 *Oncol.* 2020;27:71–4.
- 858 114. de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Laarhoven HWM, et al.
859 Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. *Eur J*
860 *Cancer.* 2020;136:132–9.
- 861 115. Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, et al. Expected
862 Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. *JCO Glob Oncol.*
863 2021;162–72.
- 864 116. Nicholson P, Ali FR, Mallipeddi R. Impact of COVID-19 on Mohs micrographic surgery: UK-
865 wide survey and recommendations for practice. *Clin Exp Dermatol.* 2020;45:901–2.
- 866 117. Walter J, Sellmer L, Kahnert K, Zauber R, Syunyaeva Z, Kauffmann-Guerrero D, et al. Daily
867 Routine and Access to Care: Initial Patient Reported Experiences at a German Lung Cancer Center
868 during the COVID-19 Pandemic. *Respiration.* 2021;100:90–2.

- 869 118. Lamblin G, Golfier F, Peron J, Moret S, Chene G, Nohuz E, et al. Impact de la pandémie de
870 Covid-19 sur les modifications thérapeutiques des patientes atteintes de cancers gynécologiques.
871 Gynécologie Obstétrique Fertil Sénologie. 2020;48:777–83.
- 872 119. Medas F, Ansaldo GL, Avenia N, Basili G, Bononi M, Bove A, et al. Impact of the COVID-19
873 pandemic on surgery for thyroid cancer in Italy: nationwide retrospective study. Br J Surg.
874 2021;108:e166–7.
- 875 120. Tejedor P, Simó V, Arredondo J, López-Rojo I, Baixauli J, Jiménez LM, et al. The impact of
876 SARS-CoV-2 infection on the surgical management of colorectal cancer: Lessons learned from a
877 multicenter study in Spain. Rev Esp Enfermedades Dig [Internet]. 2020 [cited 2022 Feb 17];113.
878 Available from: <https://online.reed.es/fichaArticulo.aspx?iarf=687768749234-416277197164>
- 879 121. Teckie S, Andrews JZ, Chen WC-Y, Goenka A, Koffler D, Adair N, et al. Impact of the COVID-
880 19 Pandemic Surge on Radiation Treatment: Report From a Multicenter New York Area Institution.
881 JCO Oncol Pract. 2021;17:e1270–7.
- 882 122. Chang EI, Liu JJ. Flattening the curve in oncologic surgery: Impact of Covid-19 on surgery at
883 tertiary care cancer center. J Surg Oncol. 2020;122:602–7.
- 884 123. Bolenz C, Vogel T, Morakis P, Mayr R, Marx M, Burger M. Uroonkologische Therapie in der
885 ersten Welle der COVID-19-Pandemie: Was sagen uns die Krebsregister der deutschen Bundesländer?
886 Urol. 2021;60:291–300.
- 887 124. Maluchnik M, Podwójcic K, Więckowska B. Decreasing access to cancer diagnosis and treatment
888 during the COVID-19 pandemic in Poland. Acta Oncol. 2021;60:28–31.
- 889 125. Polan C, Burggraf M, Kauther MD, Meyer H-L, Rademacher F, Braitsch H, et al. Development
890 of Case Numbers during the COVID-19 Pandemic in a Center of Maximum-Care for Traumatology
891 and Orthopedic Oncology. Healthcare. 2020;9:3.

- 892 126. Oba A, Stoop TF, Löhr M, Hackert T, Zyromski N, Nealon WH, et al. Global Survey on
893 Pancreatic Surgery During the COVID-19 Pandemic. *Ann Surg.* 2020;272:e87–93.
- 894 127. Rebecchi F, Arolfo S, Ugliono E, Morino M, Asti E, Bonavina L, et al. Impact of COVID-19
895 outbreak on esophageal cancer surgery in Northern Italy: lessons learned from a multicentric snapshot.
896 *Dis Esophagus.* 2021;34:doaa124.
- 897 128. PelvEx Collaborative, Chok AY, Kontovounisios C, Rasheed S, Kelly ME, Agj A, et al. The
898 impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent
899 Rectal Cancer. *Br J Surg.* 2020;107:e547–8.
- 900 129. Maccagnano C, Rocchini L, Montanari E, Conti GN, Petralia G, Dehò F, et al. Overview of the
901 italian experience in surgical management of bladder cancer during first month of COVID-19
902 pandemic. *Arch Ital Urol E Androl [Internet].* 2020 [cited 2022 Feb 17];92. Available from:
903 <https://www.pagepressjournals.org/index.php/aiua/article/view/aiua.2020.4.275>
- 904 130. de la Portilla de Juan F, Reyes Díaz ML, Ramallo Solía I. Impact of the pandemic on surgical
905 activity in colorectal cancer in Spain. Results of a national survey. *Cir Esp Engl Ed.* 2021;99:500–5.
- 906 131. Brunner M, Krautz C, Kersting S, Weber GF, Stinner B, Benz SR, et al. Oncological colorectal
907 surgery during the COVID-19 pandemic—a national survey. *Int J Colorectal Dis.* 2020;35:2219–25.
- 908 132. Gasparri ML, Gentilini OD, Lueftner D, Kuehn T, Kaidar-Person O, Poortmans P. Changes in
909 breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of
910 the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). *The Breast.*
911 2020;52:110–5.
- 912 133. The Italian Colorectal Anastomotic Leakage (iCral) study group, Caricato M, Baiocchi GL, Crafa
913 F, Scabini S, Brisinda G, et al. Colorectal surgery in Italy during the Covid19 outbreak: a survey from
914 the iCral study group. *Updat Surg.* 2020;72:249–57.

- 915 134. Thaler M, Khosravi I, Leithner A, Papagelopoulos PJ, Ruggieri P. Impact of the COVID-19
916 pandemic on patients suffering from musculoskeletal tumours. *Int Orthop*. 2020;44:1503–9.
- 917 135. Higgins E, Walters S, Powell E, Staffurth J. The Impact of the Acute Phase of COVID-19 on
918 Radiotherapy Demand in South East Wales. *Clin Oncol*. 2020;32:e217.
- 919 136. Spencer K, Jones CM, Girdler R, Roe C, Sharpe M, Lawton S, et al. The impact of the COVID-
920 19 pandemic on radiotherapy services in England, UK: a population-based study. *Lancet Oncol*.
921 2021;22:309–20.
- 922 137. Nieder C, Haukland EC, Mannsaker B, Yobuta R. Palliative Radiotherapy During the Last Month
923 of Life: Have COVID-19 Recommendations Led to Reduced Utilization? *In Vivo*. 2021;35:649–52.
- 924 138. Roberge D, Delouya G, Bohigas A, Michalowski S. Catching the Wave: Quantifying the Impact
925 of COVID on Radiotherapy Delivery. *Curr Oncol*. 2020;28:152–8.
- 926 139. Clark JJ, Dwyer D, Pinwill N, Clark P, Johnson P, Hackshaw A. The effect of clinical decision
927 making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in
928 England: a retrospective analysis. *Lancet Oncol*. 2021;22:66–73.
- 929 140. Baxter MA, Murphy J, Cameron D, Jordan J, Crearie C, Lilley C, et al. The impact of COVID-
930 19 on systemic anticancer treatment delivery in Scotland. *Br J Cancer*. 2021;124:1353–6.
- 931 141. Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, et al. Impact of the
932 COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. *JCO Glob Oncol*. 2020;1428–
933 38.
- 934 142. Pendyala P, Goglia AG, Mattes MD, Grann A, Huang D, Wagman RT, et al. Impact of the
935 Coronavirus Disease of 2019 Pandemic on Radiation Oncology Clinical Decision Making in a High-
936 Prevalence Environment. *Adv Radiat Oncol*. 2021;6:100680.

- 937 143. Kuitunen I, Ponkilainen VT, Uimonen MM, Paloneva J, Launonen AP, Mattila VM. Postponing
938 elective surgery due to COVID-19 did not decrease the oncological surgery rate in Finland. *Br J Surg.*
939 2021;108:e191–3.
- 940 144. Engelina, S., Watson, L., O’Connell, D., Kennedy, M., Ilchyshyn, A. Effects of COVID-19 on
941 the 2-week-wait dermatology services at a regional centre between 2019 and 2020. *Br J Dermatol.*
942 2020;208–208.
- 943 145. Depypere LP, Daddi N, Gooseman MR, Batirel HF, Brunelli A. The impact of coronavirus disease
944 2019 on the practice of thoracic oncology surgery: a survey of members of the European Society of
945 Thoracic Surgeons (ESTS). *Eur J Cardiothorac Surg.* 2020;58:752–62.
- 946 146. Earnshaw CH, Hunter HJA, McMullen E, Griffiths CEM, Warren RB. Reduction in skin cancer
947 diagnosis, and overall cancer referrals, during the COVID-19 pandemic. *Br J Dermatol.*
948 2020;183:792–4.
- 949 147. Muñoz-Martínez S, Sapena V, Forner A, Nault J-C, Sapisochin G, Rimassa L, et al. Assessing
950 the impact of COVID-19 on liver cancer management (CERO-19). *JHEP Rep.* 2021;3:100260.
- 951 148. Bogani G, Apolone G, Ditto A, Scambia G, Panici PB, Angioli R, et al. Impact of COVID-19 in
952 gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. *J Gynecol Oncol.*
953 2020;31:e92.
- 954 149. Sadler D, DeCara JM, Herrmann J, Arnold A, Ghosh AK, Abdel-Qadir H, et al. Perspectives on
955 the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International
956 Collaborative Network survey. *Cardio-Oncol.* 2020;6:1–13.
- 957 150. Kamarajah SK, Markar SR, Singh P, Griffiths EA, Oesophagogastric Anastomosis Audit Group.
958 The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international
959 survey of esophagogastric surgeons. *Dis Esophagus.* 2020;33:doaa054.

- 960 151. Mason SE, Scott AJ, Markar SR, Clarke JM, Martin G, Winter Beatty J, et al. Insights from a
961 global snapshot of the change in elective colorectal practice due to the COVID-19 pandemic. Fong
962 ZV, editor. PLOS ONE. 2020;15:e0240397.
- 963 152. Frey MK, Ellis AE, Zeligs K, Chapman-Davis E, Thomas C, Christos PJ, et al. Impact of the
964 coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer. *Am J Obstet*
965 *Gynecol.* 2020;223:725.e1-725.e9.
- 966 153. Martinelli F, Garbi A. Change in practice in gynecologic oncology during the COVID-19
967 pandemic: a social media survey. *Int J Gynecol Cancer.* 2020;30:1101–7.
- 968 154. Elkrief A, Kazandjian S, Bouganim N. Changes in Lung Cancer Treatment as a Result of the
969 Coronavirus Disease 2019 Pandemic. *JAMA Oncol.* 2020;6:1805.
- 970 155. Reuter-Oppermann M, Müller-Polyzou R, Wirtz H, Georgiadis A. Influence of the pandemic
971 dissemination of COVID-19 on radiotherapy practice: A flash survey in Germany, Austria and
972 Switzerland. Chun S, editor. PLOS ONE. 2020;15:e0233330.
- 973 156. Bartels MMTJ, Gal R, van der Velden JM, Verhoeff JJC, Verlaan JJ, Verkooijen HM. Impact of
974 the COVID-19 pandemic on quality of life and emotional wellbeing in patients with bone metastases
975 treated with radiotherapy: a prospective cohort study. *Clin Exp Metastasis.* 2021;38:209–17.
- 976 157. Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, et al. Survey of the Impact
977 of COVID-19 on Oncologists' Decision Making in Cancer. *JCO Glob Oncol.* 2020;1248–57.
- 978 158. Baffert K-A, Darbas T, Lebrun-Ly V, Pestre-Munier J, Peyramaure C, Descours C, et al. Quality
979 of Life of Patients With Cancer During the COVID-19 Pandemic. *In Vivo.* 2021;35:663–70.
- 980 159. Aeppli S, Eboulet E, Eisen T, Escudier B, Fischer S, Larkin J, et al. Impact of COVID-19
981 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open.*
982 2020;5:e000852.

- 983 160. Chang, P. J., Jay, G. M., Kalpakjian, C., Andrews, C., Smith, S. Patient and provider-reported
984 satisfaction of cancer rehabilitation telemedicine visits during the COVID-19 pandemic. *PM&R*.
985 2021;13:1362–8.
- 986 161. Mitchell RD, O’Reilly GM, Mitra B, Smit DV, Miller J, Cameron PA. Impact of COVID-19 State
987 of Emergency restrictions on presentations to two Victorian emergency departments. *Emerg Med*
988 *Australas*. 2020;32:1027–33.
- 989 162. Vanni G, Legramante JM, Pellicciaro M, De Carolis G, Cotesta M, Materazzo M, et al. Effect of
990 Lockdown in Surgical Emergency Accesses: Experience of a COVID-19 Hospital. *In Vivo*.
991 2020;34:3033–8.
- 992 163. Mansfield KE, Mathur R, Tazare J, Henderson AD, Mulick AR, Carreira H, et al. Indirect acute
993 effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study.
994 *Lancet Digit Health*. 2021;3:e217–30.
- 995 164. Stephenson E, Butt DA, Gronsbell J, Ji C, O’Neill B, Crampton N, et al. Changes in the top 25
996 reasons for primary care visits during the COVID-19 pandemic in a high-COVID region of Canada.
997 Leong C, editor. *PLOS ONE*. 2021;16:e0255992.
- 998 165. Fujisawa, Rie. Impact of the COVID-19 pandemic on cancer care in OECD countries, OECD
999 Health Working Paper. [Forthcoming].
- 1000 166. Sloan M, Lever E, Harwood R, Gordon C, Wincup C, Blane M, et al. Telemedicine in
1001 rheumatology: a mixed methods study exploring acceptability, preferences and experiences among
1002 patients and clinicians. *Rheumatology*. 2021;keab796.
- 1003 167. Elam AR, Sidhom D, Ugoh P, Andrews CA, De Lott LB, Woodward MA, et al. Disparities in
1004 Eye Care Utilization During the COVID-19 Pandemic. *Am J Ophthalmol*. 2022;233:163–70.

1005 168. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the
1006 COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national,
1007 population-based, modelling study. *Lancet Oncol.* 2020;21:1023–34.

1008 169. Seretis K, Boptsi E, Boptsi A, Lykoudis EG. The impact of treatment delay on skin cancer in
1009 COVID-19 era: a case-control study. *World J Surg Oncol.* 2021;19:350.

1010 170. Reuters. Facing new COVID wave, Dutch delay care for cancer, heart patients. [Internet]. 2021
1011 [cited 2022 Jan 18]. Available from: [https://www.reuters.com/world/europe/facing-new-covid-wave-](https://www.reuters.com/world/europe/facing-new-covid-wave-dutch-delay-care-cancer-heart-patients-2021-11-19/)
1012 [dutch-delay-care-cancer-heart-patients-2021-11-19/](https://www.reuters.com/world/europe/facing-new-covid-wave-dutch-delay-care-cancer-heart-patients-2021-11-19/)

1013 171. Aboulenein A. (Reuters). Overwhelmed by Omicron surge, U.S. hospitals delay surgeries
1014 [Internet]. [cited 2022 Jan 25]. Available from: [https://www.reuters.com/world/us/overwhelmed-by-](https://www.reuters.com/world/us/overwhelmed-by-omicron-surge-us-hospitals-delay-surgeries-2022-01-07/)
1015 [omicron-surge-us-hospitals-delay-surgeries-2022-01-07/](https://www.reuters.com/world/us/overwhelmed-by-omicron-surge-us-hospitals-delay-surgeries-2022-01-07/)

1016 172. European Cancer Organization. “Time to Act Data Navigator” [Internet]. [cited 2021 Dec 9].
1017 Available from: <https://www.europeancancer.org/data-navigator/#>

1018 173. International Agency for Research on Cancer WHO. Global Cancer Observatory [Internet]. [cited
1019 2022 Jan 8]. Available from: <https://gco.iarc.fr/about-the-gco>

1020

1021

1022

1023

1024 **Supporting information**

1025 **S1 Table – Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for**

1026 **Scoping Reviews (PRISMA-ScR) Checklist**

1027 **S2 Doc – Search strategy**

1028 **S3 Table – Data Extraction Form**

1029 **S4 Table – Characteristics of the studies included in the review, and from which indicators were**
1030 **extracted and collated**

1031

1032